Total Payments
$753.84
2021 Payments
$13.47
Companies
7
Transactions
11
Medicare Patients
14,198
Medicare Billing
$1.6M
Payment Breakdown by Category
Food & Beverage$753.84 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $753.84 | 11 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $248.31 | 2 | $0 (2019) |
| TOPCON MEDICAL SYSTEMS, INC. | $217.37 | 2 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $121.83 | 1 | $0 (2018) |
| Genentech USA, Inc. | $76.15 | 1 | $0 (2019) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $39.03 | 2 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $27.54 | 2 | $0 (2021) |
| Aerie Pharmaceuticals, Inc. | $23.61 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $13.47 | 1 | Novartis Pharmaceuticals Corporation ($13.47) |
| 2020 | $58.26 | 3 | Aerie Pharmaceuticals, Inc. ($23.61) |
| 2019 | $287.08 | 3 | Regeneron Healthcare Solutions, Inc. ($125.00) |
| 2018 | $263.59 | 3 | Regeneron Healthcare Solutions, Inc. ($123.31) |
| 2017 | $131.44 | 1 | TOPCON MEDICAL SYSTEMS, INC. ($131.44) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/10/2021 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/04/2020 | Novartis Pharmaceuticals Corporation | DUREZOL (Drug) | Food and Beverage | Cash or cash equivalent | $14.07 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/20/2020 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $20.58 | General |
| Category: OPHTHALMOLOGY | ||||||
| 01/27/2020 | Aerie Pharmaceuticals, Inc. | rocklatan (Drug), rhopressa | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: Glaucoma | ||||||
| 10/17/2019 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/13/2019 | TOPCON MEDICAL SYSTEMS, INC. | OCT TRITON (Device), OCT MAESTRO | Food and Beverage | Cash or cash equivalent | $85.93 | General |
| Category: OPHTHALMIC INSTRUMENT | ||||||
| 03/22/2019 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $76.15 | General |
| Category: Ophthalmology | ||||||
| 12/24/2018 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/02/2018 | Regeneron Healthcare Solutions, Inc. | EYLEA AFLIBERCEPT INJECTION (Biological) | Food and Beverage | In-kind items and services | $123.31 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/26/2018 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $121.83 | General |
| 11/12/2017 | TOPCON MEDICAL SYSTEMS, INC. | OCT-MAESTRO (Device) | Food and Beverage | Cash or cash equivalent | $131.44 | General |
| Category: OPHTHALMIC INSTRUMENT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 3,678 | 6,270 | $1.1M | $446,780 |
| 2022 | 14 | 3,512 | 5,906 | $920,748 | $364,181 |
| 2021 | 15 | 3,653 | 6,154 | $929,206 | $398,056 |
| 2020 | 15 | 3,355 | 5,533 | $860,756 | $385,504 |
Total Patients
14,198
Total Services
23,863
Medicare Billing
$1.6M
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Established patient complete exam of visual system | Office | 2023 | 892 | 1,589 | $278,075 | $164,851 | 59.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 20 | 186 | $186,000 | $127,169 | 68.4% |
| 92134 | Imaging of retina | Office | 2023 | 957 | 1,667 | $250,050 | $58,133 | 23.2% |
| 67028 | Injection of drug into eye | Office | 2023 | 70 | 279 | $139,500 | $27,874 | 20.0% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 911 | 1,553 | $93,180 | $19,944 | 21.4% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 113 | 113 | $22,600 | $12,811 | 56.7% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 48 | 155 | $15,500 | $8,561 | 55.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 67 | 107 | $13,375 | $8,282 | 61.9% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 343 | 343 | $17,150 | $7,524 | 43.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 37 | 38 | $13,300 | $4,752 | 35.7% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 99 | 117 | $7,605 | $2,459 | 32.3% |
| 92250 | Photography of the retina | Office | 2023 | 71 | 72 | $7,200 | $2,182 | 30.3% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 26 | 26 | $3,250 | $1,445 | 44.5% |
| 92133 | Imaging of optic nerve | Office | 2023 | 24 | 25 | $3,750 | $792.71 | 21.1% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 827 | 1,416 | $247,800 | $148,798 | 60.0% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 17 | 301 | $124,433 | $67,020 | 53.9% |
| 92134 | Imaging of retina | Office | 2022 | 918 | 1,526 | $228,900 | $54,727 | 23.9% |
| 67028 | Injection of drug into eye | Office | 2022 | 69 | 272 | $136,000 | $28,344 | 20.8% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2022 | 890 | 1,460 | $87,600 | $19,305 | 22.0% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 140 | 140 | $28,000 | $15,830 | 56.5% |
| 92020 | Exam of the internal drainage system of eye | Office | 2022 | 376 | 376 | $18,800 | $8,661 | 46.1% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 46 | 159 | $15,900 | $8,403 | 52.9% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 43 | 55 | $6,875 | $4,339 | 63.1% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 27 | 29 | $10,150 | $3,519 | 34.7% |
| 92250 | Photography of the retina | Office | 2022 | 46 | 49 | $4,900 | $1,612 | 32.9% |
About Dr. Alan Uliss, M.D
Dr. Alan Uliss, M.D is a Retina Specialist healthcare provider based in Forest Hills, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1902895998.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Uliss, M.D has received a total of $753.84 in payments from pharmaceutical and medical device companies, with $13.47 received in 2021. These payments were reported across 11 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($753.84).
As a Medicare-enrolled provider, Uliss has provided services to 14,198 Medicare beneficiaries, totaling 23,863 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Location Forest Hills, NY
- Active Since 10/21/2005
- Last Updated 06/23/2020
- Taxonomy Code 207WX0107X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1902895998
Products in Payments
- OCT-MAESTRO (Device) $131.44
- EYLEA (Biological) $125.00
- EYLEA AFLIBERCEPT INJECTION (Biological) $123.31
- OCT TRITON (Device) $85.93
- Lucentis (Biological) $76.15
- VYZULTA (Drug) $39.03
- rocklatan (Drug) $23.61
- DUREZOL (Drug) $14.07
- XIIDRA (Drug) $13.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.